Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 206,116,011 papers from all fields of science
Search
Sign In
Create Free Account
monoclonal antibody BIWA 4
Known as:
BIWA 4 (MAb)
, bivatuzumab
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Antibodies, Monoclonal, Humanized
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
SHIZENGAKU [BIWA/BIWAKO]: SONIC COMPLEMENT, COUNTERPOINT OR INTERPENETRATION?
John Levack Drever
2014
Corpus ID: 129254921
This copy has been supplied on the understanding that it is copyright material. Duplication or sale of all or part of any of the…
Expand
2013
2013
Drug targeting , Pharmacokinetics and Biodistribution : Differences between species
J. Klostergaard
2013
Corpus ID: 5031480
SUMMARY Hyaluronan (HA)-binding proteins, such as the cell-surface CD44 proteoglycan family and the Receptor for Hyaluronoan…
Expand
Highly Cited
2006
Highly Cited
2006
A Phase I Dose Escalation Study with Anti-CD44v6 Bivatuzumab Mertansine in Patients with Incurable Squamous Cell Carcinoma of the Head and Neck or Esophagus
B. Tijink
,
J. Buter
,
+5 authors
G. V. van Dongen
Clinical Cancer Research
2006
Corpus ID: 2599081
Purpose: To assess safety, pharmacokinetics, maximum tolerated dose, and preliminary efficacy of bivatuzumab mertansine…
Expand
2006
2006
A phase I dose escalation study with anti-CD44v6 bivatuzumab mertansine in patients with incurable squamous cell carcinoma of the head and neck or esophagus.
B. Tijink
,
J. Buter
,
+5 authors
G. V. van Dongen
Clinical cancer research : an official journal of…
2006
Corpus ID: 20551903
2004
2004
Safety, pharmacokinetics, immunogenicity, and biodistribution of (186)Re-labeled humanized monoclonal antibody BIWA 4 (Bivatuzumab) in patients with early-stage breast cancer.
M. Koppe
,
F. V. Schaijk
,
+4 authors
R. Bleichrodt
Cancer biotherapy & radiopharmaceuticals
2004
Corpus ID: 25195179
UNLABELLED The aim of this prospective study was to evaluate the safety, pharmacokinetics, immunogenicity, and biodistribution of…
Expand
Review
2003
Review
2003
CD44v6: a target for antibody-based cancer therapy
K. Heider
,
H. Kuthan
,
G. Stehle
,
G. Munzert
Cancer Immunology, Immunotherapy
2003
Corpus ID: 28447067
The human CD44 gene encodes type 1 transmembrane glycoproteins involved in cell-cell and cell-matrix interactions. The structural…
Expand
Highly Cited
2003
Highly Cited
2003
Safety, biodistribution, pharmacokinetics, and immunogenicity of 99mTc-labeled humanized monoclonal antibody BIWA 4 (bivatuzumab) in patients with squamous cell carcinoma of the head and neck
D. Colnot
,
J. Roos
,
+7 authors
G. V. van Dongen
Cancer Immunology, Immunotherapy
2003
Corpus ID: 7238713
Previous studies have shown the potential of murine and chimeric anti-CD44v6 monoclonal antibodies (MAbs) for radioimmunotherapy…
Expand
2003
2003
Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer.
E. Postema
,
P. K. Börjesson
,
+8 authors
W. Oyen
Journal of nuclear medicine : official…
2003
Corpus ID: 23586046
UNLABELLED From December 1999 until July 2001, a phase I dose escalation study was performed with (186)Re-labeled bivatuzumab, a…
Expand
2000
2000
TONAI Kakuryo, Nihon kindai biwa no kenkyu: Toriguchi, shirabeguchi wo chushin to shita “sawari” no ongaku kozo
Tadashi Shimazu
2000
Corpus ID: 185755283
1983
1983
Biwa-Hoshi : From the Viewpoint of "Marebito" Theory Part I
Norio Akasaka
1983
Corpus ID: 186075229
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
,
Terms of Service
, and
Dataset License
ACCEPT & CONTINUE